- * Subjects who have completed the preceding follow-up study ZLB07_001CR.
- * Written informed consent by the subject/parent/legally acceptable representative. Written assent for an underage subject (≥7 years and \<20 years of age at the time of obtaining informed consent), according to the competencies of the subject.
Primary Immune Deficiency
Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)
NCT01461018 | PHASE 3 | INTERVENTIONAL
The purpose of this study is to assess the long-term efficacy, tolerability, and safety of IgPro20 in subjects with primary immunodeficiency (PID) as an extension to the preceding follow-up study ZLB07_001CR (NCT01458171).
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Study site
Nagoya city,Aichi Pref.,Japan,466-8560
Study site
Chiba city,Chiba Pref.,Japan,260-8677
Study site
Fukuoka city,Fukuoka,Japan,812-8582
Study site
Gifu city,Gifu Pref.,Japan,502-8558
Study Site
Sapporo city,Hokkaido,Japan,060-8648
Study site
Moriguchi city,Osaka,Japan,570-8507
Study site
Koshigaya city,Saitama Pref.,Japan,343-8555
Study site
Tokorozawa city,Saitama Pref.,Japan,359-8513
Study site
Bunkyo-ku,Tokyo Metropolitan,Japan,113-8519
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov